PIK3CA and breast carcinoma: PIK3CA and its interaction with the AKT and mTOR pathways are the subject of numerous research studies, and therapy that inhibits PI3K, even if it had limited efficacy as monotherapy, seems promising, in a combination therapy with other inhibitors (TKIs, MEKs, PARP, respectively aromatase inhibitors in breast cancer) [4].